Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
1. A method of normalizing the expression of TOX, PLS3, and RUNX3 genes in a subject suffering from cutaneous T-cell lymphoma (CTCL) in need thereof, the method comprising:
(a) obtaining a biological sample from a subject suffering from CTCL;
(b) measuring a first expression level of the biomarkers TOX, PLS3, and RUNX3 in the biological sample;
(c) identifying the subject suffering from CTCL as a subject in need thereof based on the detection of the expression level of TOX being more than 5 fold, the expression level of PLS3 being more than 10 fold, and the expression level of RUNX3 being less than about 60% relative to the expression levels of TOX, PLS3 and RUNX3 in a subject who does not suffer from CTCL;
(d) contacting the biological sample of said subject identified in step (c) with a therapeutic agent for the treatment of CTCL;
(e) measuring a second expression level of the biomarkers TOX, PLS3 and RUNX3 in the biological sample;
(f) identifying the subject as likely to have a response to the therapeutic agent based on the detection of:
(1) the second expression levels of TOX and PLS3 being decreased as compared to the first expression levels of TOX and PLS3; and
(2) the second expression level of RUNX3 being increased as compared to the first expression level of RUNX3; and
(g) administering to said subject the therapeutic agent, thereby normalizing the expression of TOX, PLS3, and RUNX3 genes in said subject.
2. The method of claim 1 , wherein the therapeutic agent is romidepsin.
3. The method of claim 1 , wherein the second expression level is decreased by at least 30% as compared to the first expression level of TOX and PLS3.
4. The method of claim 1 , wherein the second expression level is increased by at least about 30% as compared to the first expression level of RUNX3.
5. The method of claim 1 , wherein the first and second expression levels of the at least one biomarker are determined by polymerase chain reaction (PCR), real-time PCR, quantitative real-time PCR, quantitative reverse transcription PCR, Northern Blot, Western Blot, or immunohistochemistry.
6. The method of claim 1 , wherein the biological sample is a blood sample.
7. The method of claim 6 , wherein the blood sample comprises peripheral blood mononuclear cells or peripheral blood CD4+ T-cells.
8. The method of claim 3 , wherein the second expression level is decreased by at least 50% as compared to the first expression level of TOX and PLS3.
9. The method of claim 4 , wherein the second expression level is increased by at least about 50% as compared to the first expression level of RUNX3.